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The combination of obesity and type 2 diabetes is a serious health problem, which is projected to afflict 300 million people
worldwide by 2020. Both clinical and translational laboratory studies have demonstrated that chronic inflammation is associated
with obesity and obesity-related conditions such as insulin resistance. However, the precise etiopathogenetic mechanisms linking
obesity to diabetes remain to be elucidated, and the pathways that mediate this phenomenon are not fully characterized. One of the
most recently identified signaling pathways, whose activation seems to affect many metabolic disorders, is the “inflammasome,”
a multiprotein complex composed of NLRP3 (nucleotide-binding domain and leucine-rich repeat protein 3), ASC (apoptosis-
associated speck-like protein containing a CARD), and procaspase-1. NLRP3 inflammasome activation leads to the processing
and secretion of the proinflammatory cytokines interleukin- (IL-) 1𝛽 and IL-18. The goal of this paper is to review new insights
on the effects of the NLRP3 inflammasome activation in the complex mechanisms of crosstalk between different organs, for a
better understanding of the role of chronic inflammation in metabolic disease pathogenesis. We will provide here a perspective on
the current research on NLRP3 inflammasome, which may represent an innovative therapeutic target to reverse the detrimental
metabolic consequences of the metabolic inflammation.
1. The NLRP3 Inflammasome: An Overview
The inflammasomes are signaling platforms, which are asse-
mbled in response to pathogen-associated and damage-asso-
ciated molecular pattern molecules and environmental irri-
tants. Currently, inflammasomes are distinguished into two
families: the NOD-like receptor (NLR) family and the pyrin
and HIN200 (haematopoietic interferon-inducible nuclear
antigens with 200 amino-acid repeats) domain-containing
protein (PYHIN) family. The NLR family consists of NLRP1,
NLRP2, NLRP3, NLRP6, NLRC4, and NLRP12. The PYHIN
family consists of AIM2 and IFI16. Each inflammasome is
induced by numerous different exogenous and endogenous
signals. This review will focus on the NLRP3 inflamma-
some. The NLRP3 inflammasome is a multiprotein, large
cytoplasmic complex (>700 kDa), composed of a specific
member of theNOD-like receptor protein (NLRP) subfamily,
the adaptor protein named apoptosis-associated speck-like
protein containing a CARD (ASC), and procaspase-1, which
are preferentially expressed in adipose tissue macrophages
(ATMs) [1]. Unlike the typical signaling cascades down-
stream of many innate receptors such as other NLRP mem-
bers, the NLRP3 inflammasome is a proteolytic caspase-
1-activating platform. The activation of NLRP3 leads to
oligomerization and recruitment of ASC. NLRP3 contains an
N-terminal pyrin domain (PYD), which is used to physically
interact with the PYD domain of ASC, thus facilitating
the subsequent recruitment and activation of procaspase-1.
Caspase-1 is then autocatalytically cleaved to its active form
(Figure 1). Caspase-1 does not play a major role in apoptosis.
Instead, once activated, caspase-1, as far as we are currently
aware, cleaves the proforms of two potent proinflammatory
cytokines interleukin- (IL-) 1𝛽 and IL-18 in the cytoplasm.
This has twomain effects; firstly it activates the two cytokines
and secondly in this mature form these cytokines can be
released from the cell. The active form of caspase-1 also
has the ability to induce the release of IL-1𝛼 and HMGB-1



















Figure 1: The release of obesity-related danger signals such as reactive oxygen species, lysosomes, and other obesity-induced danger signals
resulting in the oligomerization of NLRP3 in adipose tissue. The NLRP3 inflammasome is made up of carboxy terminal leucine-rich repeats
(LRRs), a nucleotide-binding domain (NBD), and an N-terminal pyrin domain (PYD).The resulting oligomerization causes the recruitment
of procaspase-1 via homotypic binding of caspase activation and recruitment domain (CARD) or through the PYD by means of the adapter
apoptosis-associated speck-like protein containing a CARD (ASC). Caspase-1 is therefore activated and initiates the cleavage of prointerleukin
(IL)1𝛽 and pro-IL18 to form the active cytokines IL1𝛽 and IL18.The activation of caspase-1 also results in pyroptosis (a form of lytic cell death
during inflammation) and the release of high mobility group box 1 (HMGB1) and IL1𝛼.
(high mobility group box 1), as well as initiate a lytic
form of cell death called pyroptosis [2–4] (Figure 1). The
primary role of the inflammasome and its products seems
to be as part of the body’s innate immune system, in
that they can be triggered to assist in the defense against
invading pathogens. Indeed much of the data published on
the inflammasome/caspase 1 is on its role in the body’s
response to microbial molecules (bacterial, fungal, or viral)
with conserved molecular structures known as “pathogen
associated molecular patterns” (PAMPs) [5, 6]. In addition
to PAMPs, the NLRP3 inflammasome is also proficient in
sensing stress to endogenous (nonmicrobial) danger signals
(“danger associated molecular patterns,” DAMPs) from dam-
aged cells. DAMPs can include molecules such as reactive
oxygen species (ROS), adenosine triphosphate (ATP), hypo-
tonic stress, uric acid crystals, or noxious exogenous factors
such as environmental insults, asbestos, andUV radiation [7].
There are a number of potential mechanisms for the
assembly of the NLRP3 inflammasome, as described earlier.
According to one hypothesis, mitochondria are the principal
source of reactive oxygen species (ROS) required for inflam-
masome activation; several recent studies have implicated
ROS produced by mitochondria, rather than phagosomes,
in NLRP3 activation exerting an indirect effect on pathways
of metabolism [8, 9]. A second mechanism involves the
disruption of lysosomal membrane integrity by crystalline
materials and peptide aggregates [10, 11]. Upon uptake of
such substances, lysosomal rupture leads to the leakage of
lysosomal proteases, specifically cathepsins B and L, into
the cytosol where they could possiblymediateNLRP3 inflam-
masome activation by an as-yet-undefined cleavage event.
In addition, type-2 diabetic patients and mice fed a high-fat
diet demonstrate IL-1𝛽 production following inflammasome
activation from obesity-induced danger signals [12]. Mice
have also been shown to become glucose intolerant following
activation of the inflammasome in hematopoietic cells by the
saturated fatty acid palmitate [13]. Very recently, Vajjhala and
colleagues [14] have shed light on the molecular details of
the complex mechanisms of NLRP3 inflammasome assembly
and activation, identifying multiple binding sites on the
PYD domain of the adaptor protein ASC which allow self-
association and interaction with binding partners.
2. The NLRP3 Inflammasome in
Obesity and Type 2 Diabetes
Several in vitro, in vivo studies and clinical trials provide
evidence that supports a causative role of IL-1𝛽 in the patho-
genesis of type 2 diabetes [15], and elevation in circulating
levels of IL-1𝛽 predicts type 2 diabetes when combined
with serum IL-6 levels [16]. Prolonged IL-1𝛽 treatment has
been demonstrated to reduce the insulin-induced glucose
uptake in murine adipocytes [17]. In contrast, addition
of the IL-1𝛽 receptor antagonist to adipocytes resulted in
increased insulin sensitivity as reflected by increased levels of
phosphorylated AKT in response to insulin. Similarly, IL-1𝛽
can inhibit the insulin-stimulated glycogen synthesis in rat
hepatocytes [18]. These results were confirmed by showing
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that IL-1𝛽 knockout mice were more insulin sensitive as
compared to wild-type control animals [19]. In humans, elev-
ated plasma levels of IL-1𝛽 have been found to be predictive
of type 2 diabetes [16], and clinical studies have suggested
that treatment with the IL-1𝛽 receptor antagonist anakinra
has beneficial effects in type 2 diabetic patients [20]. A
number of recent landmark studies have pointed out a
key role for an excessive NLRP3 inflammasome activation
in the IL-1𝛽-related development of type 2 diabetes. The
association between the NLRP3 inflammasome and both
insulin resistance and obesity has been suggested by animal
studies showing that genetic ablation of NLRP3 improved
insulin sensitivity and glucose homeostasis [21]. Specifically,
adipocytes isolated from NLRP3-deficient mice showed an
increase in insulin sensitivity as determined by phosphory-
lation of Akt. In line with the rise in insulin sensitivity, IL-1𝛽
production of adipose tissue isolated from NLRP3 knockout
mice was significantly reduced as compared to white adipose
tissue from wild-type animals. Other studies [12, 13] have
shown that improvement in insulin sensitivity (increased
phosphorylation of the insulin receptor subtrate-1 and Akt)
can also be detected in liver and muscle of NLRP3 knockout
mice on a high-fat diet for 12 weeks.This effect was associated
with a significant reduction in the tissue mRNA expression
of inflammatory cytokines compared to wild-type control
[13]. Ablation of the NLRP3 in mice has been also reported
to protect from obesity-associated macrophage activation in
adipose tissue, reducing M1-like macrophage gene expres-
sion (tumor necrosis factor-𝛼, chemokine ligand 20, and
chemokine ligand 11) and increasing the expression of M2-
like cytokines (interleukin-10).This effect was associatedwith
an increase in the number of M2 macrophages in NLRP3-
deficient obese mice, without affecting the M1 macrophage
frequency [12]. To confirm the clinical relevance of these
data generated from mouse models, the same authors have
demonstrated that weight loss reduced NLRP3 expression
in abdominal subcutaneous adipose tissue in obese patients
with type 2 diabetes, which was accompanied by improved
glucose homeostasis [12]. Furthermore, strong correlations
between the expression of NLRP3 inflammasome-related
genes and insulin resistance have been recently reported
in obese male subjects with impaired glucose tolerance
[22]. Additionally, type 2 diabetic patients showed elevated
levels of NLRP3, ASC, IL-1𝛽, and IL-18 mRNA and protein
expression in monocyte-derived macrophages, compared
with those in healthy control subjects. Besides, the cleavage
of caspase-1 and release of mature IL-1𝛽 were significantly
elevated in monocyte-derived macrophages from type 2
diabetic patients compared with controls [23]. Inflammatory
cytokines are known to contribute crucially to the devel-
opment of insulin resistance by activating different kinases
that disrupt insulin signaling. The endoplasmatic reticulum
(ER) is an extensive membrane network which has been
recently demonstrated to be involved in the transduction of
cytokines effects into activation of different kinases.The early
steps of insulin biosynthesis occur in the ER of pancreatic
𝛽 cells, thus further suggesting the key role of ER load and
folding activity in the insulin biosynthesis [24]. A major
role of the ER is to ensure the synthesis and folding of
membrane and secreted proteins, and any disturbance in this
function (e.g., excessive protein synthesis or accumulation
of unfolded or misfolded proteins in the ER lumen) leads
to an “ER stress” response, also known as the unfolded
protein response (UPR). The recent literature suggests that
ER stress may act directly as a negative modulator of the
insulin biosynthesis and insulin signaling pathways but also
indirectly by promoting lipid accumulation [25, 26]. ER
stress also plays a role in the dysregulation of adipokine
secretion by adipose tissue, frequently observed in obesity
and insulin resistance [27, 28], and CD14+ monocytes iso-
lated from diabetic patients showed evidence of ER stress,
which may underlie the functional defects in these cells
[29]. Interestingly, ER stress has been recently demonstrated
to activate the NLRP3 inflammasome, resulting in the
subsequent release of IL-1𝛽 by human macrophages, with
an activation mechanism similar to that of other known
NLRP3 activators, requiring ROS generation and potassium
efflux [30]. The thioredoxin-interacting protein (TXNIP), a
critical node in the development of ER stress leading to
programmed cell death of pancreatic 𝛽 cells, activates the
NLRP3 inflammasome, causing procaspase-1 cleavage and
IL-1𝛽 secretion in human monocytic cells [31]. The role of
ER stress in promoting NLRP3 inflammasome activation is
consistent with the subcellular localization of NLRP3. In
resting cells, NLRP3 is associated with ER membranes, and
then upon activationNLRP3 is redistribute to the perinuclear
space where it colocalizes with endoplasmic reticulum and
mitochondria organelle clusters [9].
3. The NLRP3 Inflammasome and the Organ
Crosstalk in the Metabolic Inflammation
NLRP3 inflammasome plays a substantial role in sensing
obesity-associated inducers of caspase-1 activation and there-
fore regulates the magnitude of the inflammation and its
downstream effects on insulin signaling in different organs,
as reported here later.
3.1. Immune Effector Cells. NLRP3 expression is detected
mainly in the cytosol of granulocytes, monocytes, dendritic
cells, T and B cells, and osteoblasts [32]. Thus, most of
the first studies characterizing the role of NLRP3 signaling
have been conducted in cells of the immune system. Several
studies on innate immune cells have demonstrated that
the myeloid-derived NLRP3 inflammasome complex may
contribute to promote inflammatory cytokine production
and insulin resistance through reduction of insulin signaling.
In vitro experiments have shown that elevated concentration
of saturated fatty acids (SFAs), caused by a high-fat diet, may
activate the NLRP3 inflammasome in macrophages through
a newly identified AMP-activated protein kinase and unc-
51-like kinase-1 autophagy signaling cascade [13]. Besides,
both ex vivo and in vivo exposure of bone marrow derived
dendritic cells to dietary SFA resulted in increased NLRP3
inflammasome activation and reduced adipocyte insulin
sensitivity. More specifically, dietary SFA may act as a primer
of the NLRP3 inflammasome protein complex enhancing
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NLRP3, caspase-1, and pro-IL-1𝛽 mRNA expression. A sec-
ond signal is then required to induce maturation of IL-1𝛽
from inactive pro-IL-1𝛽. This second step can be triggered
by exposure to ATP, ROS, or ceramide [33]. Overall, these
data suggest that exposure to dietary SFA represents the key
metabolic stressor relevant to both priming and processing of
IL-1𝛽 in both adipocytes and innate immune cells. However,
it must be stressed that the high expression of NLRP3
in primary adipocyte fractions of enzymatically digested
adipose tissue may be attributable in large part to lipid-laden
macrophages that contaminate enriched adipocyte fractions,
as also suggested by immunofluorescence and qRT-PCR data,
showing that NLRP3 is highly expressed in adipose tissue
macrophages with low expression in adipocytes [12]. Besides,
standard isolation procedures for isolating primary adipose
cells often involve collagenase digestion, which have been
shown to be a potent inducer of cytokine gene transcrip-
tion and protein secretion [34]. These findings highlight
a new model of organ crosstalk, in which leukocyte and
macrophage recruitment in key insulin target tissues, such
as liver, adipose, and muscle, may promote insulin resistance
by enhancing inflammasome activation. This is in keeping
with recent studies showing that IL-1𝛽’s role in regulating
the endocrine function of adipose tissue is mediated by its
own ability to evoke local macrophage recruitment and lipid
accumulation in an autocrine/paracrine manner [35]. As in
diabetic patients pancreas, adipose tissue, liver, and kidney,
with infiltrated macrophages, are major sites of origin of
inflammation, itmight be intriguing to investigate the specific
contribution of NLRP3 inflammasome activation in these
different insulin target tissues and to identify the specific
inducers that selectivity participate in the mechanism of
tissue NLRP3 inflammasome activation.
3.2. Pancreas. Pancreatic islets of type 2 diabetic patients
have amyloid deposition and increased production of proin-
flammatory cytokines and chemokines. The unique, primary
component of islet amyloid deposits is the islet amyloid
polypeptide (IAPP; also known as amylin).Mice overexpress-
ing IAPPproduce higher amounts of IL-1𝛽 [36], and exposure
to high levels of IL-1𝛽 has been demonstrated to induce
beta cell death in cell culture, interfering with signaling to
NF-𝜅B through IKK𝛽 or the I𝜅B𝛼 super-repressor [37]. In
keeping with these results, neutralizing IL-1𝛽 on isolated beta
cells using IL-1 receptor antagonist significantly improves
𝛽-cell survival [38]. However, the precise mechanism(s) by
which IL-1𝛽 affects pancreatic 𝛽-cell failure is still debated.
Zhou et al. [39] were the first to identify a possible signaling
pathway involved in NLRP3 inflammasome activation under
conditions ofmetabolic stress.They showed that thioredoxin-
interacting protein (TXNIP), also known as vitamin D3
upregulated protein 1 (VDUP1), is an upstream and highly
selective activating ligand for NLRP3, with no effect on the
activity of other inflammasomes (e.g., NLRC4 and AIM2).
TXNIP-dependent NLRP3 inflammasome activation drives
IL-1𝛽 secretion from pancreatic islets in response to chronic
elevated glucose, thus suggesting, for the first time, that
NLRP3, activated under conditions ofmetabolic stress, medi-
ates IL-1𝛽-driven islet failure. Other authors have identified
oligomers of IAPP, as a key trigger for NLRP3 inflamma-
some activation and the following processing of IL-1𝛽 [40].
Obesity-induced pancreatic 𝛽-cell death is regulated, at least
in part, by the NLRP3 inflammasome, as demonstrated
in NLRP3-deficient mice in late-stage obesity, where the
ablation of NLRP3 is associated with reduced cell death and
increase in pancreatic islet size and local insulin levels [41].
3.3. Adipose Tissue. As noted by Vandanmagsar et al., the
NLRP3 inflammasome is activated in adipose tissue inmouse
models of obesity and attenuated by calorie restriction.
NLRP3 inflammasome levels also correlate with glycaemia in
type 2 diabetes patients after weight loss interventions [12].
Besides, mice deficient in inflammasome components are
protected from body-weight gain and adipocyte hypertrophy,
induced by chronic exposure to a high-fat diet [1]. NLRP3
inflammasome components have been reported to be abun-
dantly represented in adipocytes of patients with metabolic
syndrome, mainly in adipocytes from samples of visceral
adipose tissue. In contrast, the inflammasome in subcuta-
neous adipose tissue adipocytes did not seem to be grossly
influenced by the presence of the metabolic syndrome [42].
Interestingly, caspase-1 activation in adipose tissue of obese
animals takes place partly independent of macrophage infil-
tration. Partial depletion of macrophages from adipose tissue
of obese animals decreased the expression of the macrophage
marker CD68, with no significant alteration in the expression
of caspase-1, thus suggesting that the effects of the NLRP3-
ASC-caspase-1 protein complex on adipose tissue are not only
exerted though infiltrating macrophages. This observation
was also confirmed in in vitro experiments showing caspase-
1 activation in adipocytes in settings free of inflammatory
cells [43] and increased insulin sensitivity in adipocytes
lacking of caspase-1 or the inflammasome componentNLRP3
[21]. In addition, adipocyte upregulation of IL-1𝛽 expression
and secretion in response to inflammatory stimuli has been
shown to induce hepatic insulin resistance, thus suggesting a
further intriguing role for NLRP3 inflammasome activation
in the dysfunctional communication between adipocytes
and hepatocytes [35, 43]. Overall these data reveal a novel
metabolic function of the NLRP3 inflammasome in adipose
tissue, suggesting that its pharmacological modulation in
obese and/or patients with type 2 diabetes may restore
the metabolic function of adipose tissue and subsequently
improve insulin sensitivity.
3.4. Liver. The involvement of the inflammasome in nonal-
coholic fatty liver disease (NAFLD) and non-alcoholic steato-
hepatitis (NASH) is slowly being elucidated. The presence of
NLRP3 inflammasome and/or inflammasome activation has
been shown in sinusoidal endothelial cells [44], stellate cells
[45], and hepatocytes [46]. Recently, inflammasome activa-
tion has been associated with NASH, and long-term high-
fat diet administration resulted in reduced hepatic steato-
sis in NLRP3 knockout mice [12]. Selective deficiency in
IL-1𝛽 in liver parenchymal cells, but not in bone-marrow-
derived cells, protected mice from diet-induced steatohepati-
tis and fibrosis [47]. Increased mRNA expression of NLRP3
inflammasome components was found in human livers
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of NASH patients [46] where NLRP3 levels were decreased
after weight loss. These observations suggest that inflamma-
some activation by different cell types may contribute to dif-
ferent aspects of steatohepatitis. In contrast, to date, there are
no data suggesting a potential role of NLRP3 inflammasome
activation on impaired glycogen synthesis and/or augmented
glycogenolysis.
3.5. Gut. There is evidence that the inflammasome comp-
onents are important in the maintenance of the integrity of
the intestinal epithelium and the defense against pathogenic
organisms that can invade the gastrointestinal tract. For
instance, mice lacking the inflammasome components
NLRP3 and caspase-1 are hypersusceptible to gastrointestinal
inflammation induced by Citrobacter rodentium, an ent-
eric bacterial pathogen of the mouse intestinal tract that
triggers inflammatory responses resembling those of humans
infectedwith enteropathogenic and enterohemorrhagicEsch-
erichia coli. The increased host susceptibility to C. rodentium
is due to the failure to produce normal levels of IL-1𝛽 and
IL-18 in the presence of NLRP3 and Caspase-1 deficiency
[48]. NLRP3-deficient mice had been reported to show
increased susceptibility to dextran-sulfate-sodium- (DSS-)
induced colitis with increased mortality and weight loss in
three different studies [49–51]. However, other authors did
not show a negative regulatory effect of NLRP3 on colitis,
showing that NLRP3-null mice or mice pretreated with the
caspase-1 inhibitor pralnacasan had less severe colitis when
treated with DSS, which was related to decreased IL-1𝛽
secretion of DSS-exposed NLRP3-deficient macrophages
in vitro [52, 53]. This discrepancy could be due not only to
differences in protocols but also to baseline differences in
the gut microbiota that might account for the dissimilar
phenotypes. The crucial role of inflammasome components
in the impairments of the gut microbiota composition is
also suggested by recent studies demonstrating that NLRP3
inflammasome regulates the gastrointestinal microbiome
and can thereby affect host susceptibility to diseases beyond
the gastrointestinal tract, including obesity and diabetes. In
particular, modulation of the intestinal microbiota through
multiple inflammasome components has been recently
demonstrated to be a critical determinant of NAFLD/NASH
progression as well as multiple other aspects of metabolic
syndrome such as weight gain and glucose homeostasis
[54]. Inflammasome-deficiency-associated changes in the
configuration of the gut microbiota are associated with
exacerbated hepatic steatosis and inflammation through
influx of TLR4 and TLR9 agonists into the portal circulation,
leading to enhanced hepatic tumour-necrosis factor- (TNF-)
𝛼 expression that drives NASH progression [54].
3.6. Kidney. Little is known of the role of the NLRP3 inflam-
masome complex in the development of renal metabolic
damage. In humans, IL-18 and caspase-1 are expressed in
renal tubular epithelium, and patients with chronic kidney
disease or the nephrotic syndrome exhibit elevated levels of
IL-18 [55–57]. In a cohort of renal biopsies from patients
with nondiabetic kidney disease, levels of mRNA encoding
NLRP3 correlate with renal function [58], strongly suggesting
thatNLRP3 contributes to the pathogenesis of chronic kidney
disease. This is supported by experimental data showing
that inflammasome-regulated cytokines such as IL-1𝛽 and
IL-18 are implicated in animal models of chronic kidney
disease, including glomerulonephritis and renal ischemic
injury [59]. In an animal study aimed to evaluate the renal
consequences of the chronic administration of high-fructose
corn syrup (HFCS-55), the major sweetener in foods and
soft-drinks, we have recently demonstrated that HFCS-55
feeding caused a significant increase in bodyweight andmore
importantly dyslipidemia, hyperinsulinemia, and an increase
in insulin resistance due to impaired insulin signaling [60].
Most notably, the HFCS-55 diet evoked upregulation of renal
NLRP3 expression, resulting in activation of caspase-1 and
the subsequent cleavage of pro-IL1𝛽 to the biologically active
secreted form IL-1𝛽. These effects were due, at least in part,
to the marked hyperuricemia afforded by the dietary manip-
ulation, as also confirmed by a previous study demonstrating
that increased levels of uric acid directly activate the NLRP3
inflammasome [61]. Similarly, rats fed with fructose, which is
known to raise uric acid levels, showed a significant increase
in renal protein levels of NLRP3 [62]. However, one impor-
tant question that remains to be answered regards the specific
cell types involved in renal NLRP3 activation. As several
studies have shown that monocyte/macrophage recruitment
to the kidney significantly contributes to the renal injury, we
cannot rule out that the increased NLRP3 activation in the
kidney is due to an increase in the infiltrating macrophages
or, more likely, to a crosstalk between macrophages and
tubular/glomerular cells.
3.7. Skeletal Muscle. Although it has been recently proposed
that sarcopenia (loss of muscle mass) and myosteatosis (fat
infiltration in skeletal muscle) exert a key role in triggering
insulin resistance in obese patients, so far the potential role
of NLRP3 complex activation in muscle activity and muscle
production of inflammatory mediators has not yet been
investigated. However, there is evidence that components
of the inflammasome complex are upregulated in dysferlin-
deficient human muscle, thus suggesting that skeletal muscle
cells can actively participate in inflammasome activation [63].
This is a crucial point as recent studies have demonstrated
that skeletal muscle cells produce and release cytokines
(myokines) that act in an autocrine, paracrine, and/or
endocrine manner to modulate metabolic and inflammatory
process. For example, it has been demonstrated very recently
thatmuscular expression of PGC-1 alpha stimulates the secre-
tion of a newly identified myokine, irisin, which improves
glucose homeostasis and causes weight loss [64]. However,
the interactions between localNLRP3 expression/activity and
myokines production as well as the effects of these interac-
tions on muscle structure, function, and insulin-sensitivity
in animals and humans have never been investigated. Inter-
estingly, both IL-1𝛽 and IL-18 seem to exert a crucial role
also in the initiation and progression of the idiopathic
inflammatory myopathies, a heterogeneous group of chronic
disorders with predominant inflammation in muscle tissue,
including dermatomyositis, polymyositis, and myositis [65–
67]. Studies elucidating the detailed involvement of muscular
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inflammasome protein complex may thus provide promising
targets for new therapies for this heterogeneous group of
inflammatory muscle diseases.
4. NLRP3 Activation and Cardiovascular
Complications of Metabolic Disorders
Individuals with obesity and insulin resistance have an
increased burden of cardiovascular disease (CVD). In the
Kuopio Ischemic Heart Disease study, Lakka et al. [68]
reported a 4.26-fold relative risk for mortality due to heart
disease and a 1.77 relative risk for all-cause mortality in
obese, insulin-resistant patients. Similarly, in the Botnia study
the risk for coronary heart disease (CHD) and stroke was
shown to be increased threefold and the risk for cardio-
vascular mortality was increased six fold [69]. The Hoorn
Study examined 615 men and 749 women aged 50 to 75
years without diabetes or a history of CVD at baseline and
reported that the development of insulin resistance and/or
obesity was associated with about a twofold increase in
age-adjusted risk of fatal CVD in men and nonfatal CVD in
women [70]. The pathophysiological mechanism by which
metabolic disorders increase cardiovascular risk remains
under debate. Studies published during the past decade have
convincingly demonstrated a pathophysiological role for the
inflammatory response in the development of both insulin
resistance and related CVD.The finding a little over a decade
ago that the secretion of IL-1𝛽 and IL-18 was increased
in an ischemia/reperfusion (I/R) model of suprafused human
atrial myocardium [71] provided the first clear link between
inflammasome activation and CVD development. Experi-
mental studies in mice with genetic deletion of caspase-1
have identified caspase-1 inhibition as a potential target for
pharmacological intervention in the setting of CVD [72–74].
A recent report described formation of the inflammasome
in a mouse model of myocardial I/R, mainly in cardiac
fibroblasts and infiltrating cells, and reported that ASC
knockout mice were protected, with a significant decline
in cardiac infiltration of phagocytes, inflammatory cytokine
levels, infarct size, and myocardial fibrosis and dysfunction
[75].The inflammasome was also detected in cardiomyocytes
bordering the infarct zone during the infarct process, and
prevention of inflammasome activation limited infarct size
and cardiac enlargement after acute myocardial I/R injury
in the mouse [76]. NLRP3 deficiency protects mice also
from renal I/R injury [77, 78]. Both studies showed that
the absence of NLRP3 protected kidneys against renal I/R
injury to a greater extent than the absence of ASC, sug-
gesting that NLRP3 may play an additional role in renal
I/R injury independently of ASC and caspase-1. Overall, the
ability of members of the NLRP3 inflammasome protein
complex to target molecular and cellular pathways involved
in both metabolic and cardiovascular diseases suggest that
selective pharmacological modulation of NLRP3 inflam-
masome has the potential to exert synergistic effects in
the control of metabolic disorders and its cardiovascular
complications. Thus, this unique therapeutic strategy could
decrease the burden of cardiovascular morbidity and mor-
tality in the presence of obesity and insulin resistance,
although, to date, there are no clinical data to support this
concept.
5. Conclusions
In conclusion, NLRP3 inflammasome is a novel protein
complex that integrates multiple exogenous and endogenous
danger signals into the immediate secretion of IL-1𝛽 and IL-
18. Most recent data suggest that activation of the NLRP3
inflammasome complex contributes to the pathophysiolog-
ical mechanisms that explain the development of visceral
obesity and insulin resistance.Thanks to its wide distribution
in different tissues and organs, the NLRP3 inflammasome
protein complex may represent a crucial signaling pathway
that facilitates organ crosstalk and local injury in tissues
target of metabolic damage. A better understanding of this
novel pathway could help to clarify the crucial role of the
molecularmechanisms of interorgan crosstalk during obesity
and insulin resistance development. Studies using animal
models and human biopsies will be useful to determine
the spatial and temporal expression of inflammasome com-
ponents inside the organs and to correlate these findings
with disease activity or prognosis. Gene polymorphism
studies on suitable patient cohorts could help to determine
the functional significance of the protein expression data.
Finally, the identification of selective pharmacological tools
able to affect expression and/or activity of this novel pathway
could represent the ultimate proof of significance of the
inflammasome-caspase-1-IL-1𝛽/18 axis in the development
of metabolic inflammation. The effects evoked by these
novel pharmacological tools should be compared with effects
obtained by targeting selective cytokine receptor activities in
order to better elucidate the potential crucial role of NLRP3
inflammasome protein complex in mediating inflammatory
diseases. This approach may not only offer a potentially
fruitful area of research, but it will also hopefully lead to
novel and specific therapies for obesity-related conditions
such as insulin resistance and its associated cardiovascular
complications.
References
[1] R. Stienstra, J. A. van Diepen, C. J. Tack et al., “Inflammasome
is a central player in the induction of obesity and insulin
resistance,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 108, no. 37, pp. 15324–15329,
2011.
[2] J. P.-Y. Ting, S. B. Willingham, and D. T. Bergstralh, “NLRs at
the intersection of cell death and immunity,” Nature Reviews
Immunology, vol. 8, no. 5, pp. 372–379, 2008.
[3] G. Yeretssian, K. Labbe´, and M. Saleh, “Molecular regulation of
inflammation and cell death,” Cytokine, vol. 43, no. 3, pp. 380–
390, 2008.
[4] M. K. Atianand, V. A. Rathinam, and K. A. Fitzgerald, “Snap-
Shot: inflammasomes,” Cell, vol. 153, pp. 272–272.e1, 2013.
[5] L. Franchi, R. Mun˜oz-Planillo, T. Reimer, T. Eigenbrod, and
G. Nu´n˜ez, “Inflammasomes as microbial sensors,” European
Journal of Immunology, vol. 40, no. 3, pp. 611–615, 2010.
Mediators of Inflammation 7
[6] T.-D. Kanneganti, “Central roles of NLRs and inflammasomes
in viral infection,” Nature Reviews Immunology, vol. 10, no. 10,
pp. 688–698, 2010.
[7] G. Y. Chen and G. Nun˜ez, “Sterile inflammation: sensing and
reacting to damage,” Nature Reviews Immunology, vol. 10, no.
12, pp. 826–837, 2010.
[8] K. Nakahira, J. A. Haspel, V. A. K. Rathinam et al., “Autophagy
proteins regulate innate immune responses by inhibiting the
release of mitochondrial DNA mediated by the NALP3 inflam-
masome,” Nature Immunology, vol. 12, no. 3, pp. 222–230, 2011.
[9] R. Zhou, A. S. Yazdi, P. Menu, and J. Tschopp, “A role for mito-
chondria inNLRP3 inflammasome activation,”Nature, vol. 469,
pp. 221–225, 2011.
[10] A. Halle, V. Hornung, G. C. Petzold et al., “The NALP3 inflam-
masome is involved in the innate immune response to amyloid-
𝛽,” Nature Immunology, vol. 9, no. 8, pp. 857–865, 2008.
[11] V. Hornung, F. Bauernfeind, A. Halle et al., “Silica crystals and
aluminum salts activate the NALP3 inflammasome through
phagosomal destabilization,” Nature Immunology, vol. 9, no. 8,
pp. 847–856, 2008.
[12] B. Vandanmagsar, Y.-H. Youm, A. Ravussin et al., “The NLRP3
inflammasome instigates obesity-induced inflammation and
insulin resistance,” Nature Medicine, vol. 17, no. 2, pp. 179–188,
2011.
[13] H. Wen, D. Gris, Y. Lei et al., “Fatty acid-induced NLRP3-ASC
inflammasome activation interferes with insulin signaling,”
Nature Immunology, vol. 12, no. 5, pp. 408–415, 2011.
[14] P. R. Vajjhala, R. E. Mirams, and J. M. Hill, “Multiple binding
sites on the pyrin domain of ASC protein allow self-association
and interaction with NLRP3 protein,” The Journal of Biological
Chemistry, vol. 287, pp. 41732–41743, 2012.
[15] C. A. Dinarello, M. Y. Donath, and T. Mandrup-Poulsen, “Role
of IL-1𝛽 in type 2 diabetes,” Current Opinion in Endocrinology,
Diabetes and Obesity, vol. 17, no. 4, pp. 314–321, 2010.
[16] J. Spranger, A. Kroke,M.Mo¨hlig et al., “Inflammatory cytokines
and the risk to develop type 2 diabetes: results of the prospec-
tive population-based European Prospective Investigation into
Cancer and Nutrition (EPIC)-Potsdam study,”Diabetes, vol. 52,
no. 3, pp. 812–817, 2003.
[17] J. Jager, T. Gre´meaux, M. Cormont, Y. Le Marchand-Brustel,
and J.-F. Tanti, “Interleukin-1𝛽-induced insulin resistance
in adipocytes through down-regulation of insulin receptor
substrate-1 expression,” Endocrinology, vol. 148, no. 1, pp. 241–
251, 2007.
[18] T. Kanemaki, H. Kitade, M. Kaibori et al., “Interleukin 1𝛽 and
interleukin 6, but not tumor necrosis factor 𝛼, inhibit insulin-
stimulated glycogen synthesis in rat hepatocytes,” Hepatology,
vol. 27, no. 5, pp. 1296–1303, 1998.
[19] P. A. Cleary, T. J. Orchard, S. Genuth et al., “The effect of inten-
sive glycemic treatment on coronary artery calcification in type
1 diabetic participants of the diabetes control and complications
trial/epidemiology of diabetes interventions and complications
(DCCT/EDIC) study,” Diabetes, vol. 55, no. 12, pp. 3556–3565,
2006.
[20] C. M. Larsen, M. Faulenbach, A. Vaag et al., “Interleukin-
1-receptor antagonist in type 2 diabetes mellitus,” The New
England Journal ofMedicine, vol. 356, no. 15, pp. 1517–1526, 2007.
[21] R. Stienstra, L. A. B. Joosten, T. Koenen et al., “The inflamma-
some-mediated caspase-1 activation controls adipocyte differ-
entiation and insulin sensitivity,” Cell Metabolism, vol. 12, no. 6,
pp. 593–605, 2010.
[22] G. H. Goossens, E. E. Blaak, R. Theunissen et al., “Expression
of NLRP3 inflammasome and T cell population markers in adi-
pose tissue are associated with insulin resistance and impaired
glucosemetabolism in humans,”Molecular Immunology, vol. 50,
no. 3, pp. 142–149, 2012.
[23] H. M. Lee, J. J. Kim, H. J. Kim, M. Shong, B. J. Ku, and E. K. Jo,
“Upregulated NLRP3 inflammasome activation in patients with
type 2 diabetes,” Diabetes, vol. 62, pp. 194–204, 2013.
[24] H. P. Harding and D. Ron, “Endoplasmic reticulum stress
and the development of diabetes: a review,” Diabetes, vol. 51,
supplement 3, pp. S455–S461, 2002.
[25] M. Cnop, F. Foufelle, and L. A. Velloso, “Endoplasmic reticulum
stress, obesity and diabetes,” Trends in Molecular Medicine, vol.
18, no. 1, pp. 59–68, 2012.
[26] M. Flamment, E. Hajduch, P. Ferre, and F. Foufelle, “New
insights into ER stress-induced insulin resistance,” Trends in
Endocrinology & Metabolism, vol. 23, pp. 381–390, 2012.
[27] L. Xu, G. A. Spinas, and M. Niessen, “ER stress in adipocytes
inhibits insulin signaling, represses lipolysis, and alters the
secretion of adipokines without inhibiting glucose transport,”
Hormone and Metabolic Research, vol. 42, no. 9, pp. 643–651,
2010.
[28] J. Deng, S. Liu, L. Zou, C. Xu, B. Geng, and G. Xu, “Lipolysis
response to endoplasmic reticulum stress in adipose cells,”The
Journal of Biological Chemistry, vol. 287, no. 9, pp. 6240–6249,
2012.
[29] T. Komura, Y. Sakai, M. Honda, T. Takamura, K. Matsushima,
and S. Kaneko, “CD14+monocytes are vulnerable and function-
ally impaired under endoplasmic reticulum stress in patients
with type 2 diabetes,”Diabetes, vol. 59, no. 3, pp. 634–643, 2010.
[30] P.Menu,A.Mayor, R. Zhou et al., “ER stress activates theNLRP3
inflammasome via an UPR-independent pathway,” Cell Death
and Disease, vol. 3, no. 1, article e261, 2012.
[31] A. G. Lerner, J. P. Upton, P. V. Praveen et al., “IRE1alpha
induces thioredoxin-interacting protein to activate the NLRP3
inflammasome and promote programmed cell death under
irremediable ER stress,” Cell Metabolism, vol. 16, pp. 250–264,
2012.
[32] J. A. Kummer, R. Broekhuizen, H. Everett et al., “Inflammasome
componentsNALP 1 and 3 showdistinct but separate expression
profiles in human tissues suggesting a site-specific role in
the inflammatory response,” Journal of Histochemistry and
Cytochemistry, vol. 55, no. 5, pp. 443–452, 2007.
[33] C. M. Reynolds, F. C. McGillicuddy, K. A. Harford, O. M. Fin-
ucane, K. H. Mills, and H. M. Roche, “Dietary saturated fatty
acids prime the NLRP3 inflammasome via TLR4 in dendritic
cells-implications for diet-induced insulin resistance,” Molecu-
lar Nutrition & Food Research, vol. 56, pp. 1212–1222, 2012.
[34] H. Ruan, M. J. Zarnowski, S. W. Cushman, and H. F. Lodish,
“Standard isolation of primary adipose cells from mouse epi-
didymal fat pads induces inflammatory mediators and down-
regulates adipocyte genes,”The Journal of Biological Chemistry,
vol. 278, no. 48, pp. 47585–47593, 2003.
[35] O.Nov,H. Shapiro,H.Ovadia et al., “Interleukin-1beta regulates
fat-liver crosstalk in obesity by auto-paracrine modulation of
adipose tissue inflammation and expandability,” PLoS One, vol.
8, Article ID e53626, 2013.
[36] T. Mandrup-Poulsen, “IAPP boosts islet macrophage IL-1 in
type 2 diabetes,”Nature Immunology, vol. 11, no. 10, pp. 881–883,
2010.
[37] J. J. Collier, S. J. Burke, M. E. Eisenhauer et al., “Pancreatic 𝛽-
cell death in response to pro-inflammatory cytokines is distinct
8 Mediators of Inflammation
from genuine apoptosis,” PLoS ONE, vol. 6, no. 7, Article ID
e22485, 2011.
[38] A. Ardestani, N. S. Sauter, F. Paroni et al., “Neutralizing int-
erleukin-1𝛽(IL-1𝛽) induces𝛽-cell survival bymaintaining PDX1
protein nuclear localization,” The Journal of Biological Chem-
istry, vol. 286, no. 19, pp. 17144–17155, 2011.
[39] R. Zhou, A. Tardivel, B. Thorens, I. Choi, and J. Tschopp,
“Thioredoxin-interacting protein links oxidative stress to infla-
mmasome activation,” Nature Immunology, vol. 11, no. 2, pp.
136–140, 2010.
[40] S. L. Masters, A. Dunne, S. L. Subramanian et al., “Activation
of the NLRP3 inflammasome by islet amyloid polypeptide
provides a mechanism for enhanced IL-1𝛽 2 in type 2 diabetes,”
Nature Immunology, vol. 11, no. 10, pp. 897–904, 2010.
[41] Y.-H. Youm, A. Adijiang, B. Vandanmagsar, D. Burk, A.
Ravussin, and V. D. Dixit, “Elimination of the NLRP3-ASC
inflammasome protects against chronic obesity-induced pan-
creatic damage,” Endocrinology, vol. 152, no. 11, pp. 4039–4045,
2011.
[42] S. Madec, C. Rossi, M. Chiarugi et al., “Adipocyte P2X7 recep-
tors expression: a role in modulating inflammatory response in
subjects withmetabolic syndrome?”Atherosclerosis, vol. 219, no.
2, pp. 552–558, 2011.
[43] O. Nov, A. Kohl, E. C. Lewis et al., “Interleukin-1𝛽may mediate
insulin resistance in liver-derived cells in response to adipocyte
inflammation,” Endocrinology, vol. 151, no. 9, pp. 4247–4256,
2010.
[44] A. B. Imaeda, A.Watanabe,M.A. Sohail et al., “Acetaminophen-
induced hepatotoxicity in mice is dependent on Tlr9 and the
Nalp3 inflammasome,”The Journal of Clinical Investigation, vol.
119, no. 2, pp. 305–314, 2009.
[45] A.Watanabe, M. A. Sohail, D. A. Gomes et al., “Inflammasome-
mediated regulation of hepatic stellate cells,” American Journal
of Physiology, vol. 296, no. 6, pp. G1248–G1257, 2009.
[46] T. Csak, M. Ganz, J. Pespisa, K. Kodys, A. Dolganiuc, and
G. Szabo, “Fatty acid and endotoxin activate inflammasomes
in mouse hepatocytes that release danger signals to stimulate
immune cells,” Hepatology, vol. 54, no. 1, pp. 133–144, 2011.
[47] Y. Kamari, A. Shaish, E. Vax et al., “Lack of interleukin-
1𝛼 or interleukin-1𝛽 inhibits transformation of steatosis to
steatohepatitis and liver fibrosis in hypercholesterolemic mice,”
Journal of Hepatology, vol. 55, no. 5, pp. 1086–1094, 2011.
[48] Z. Liu, M. H. Zaki, P. Vogel et al., “Role of inflammasomes in
host defense against Citrobacter rodentium infection,”The Jour-
nal of Biological Chemistry, vol. 287, pp. 16955–16964, 2012.
[49] I. C. Allen, E.M. Tekippe, R.-M. T.Woodford et al., “TheNLRP3
inflammasome functions as a negative regulator of tumorige-
nesis during colitis-associated cancer,” Journal of Experimental
Medicine, vol. 207, no. 5, pp. 1045–1056, 2010.
[50] M.H. Zaki, K. L. Boyd, P. Vogel,M. B. Kastan,M. Lamkanfi, and
T.-D. Kanneganti, “The NLRP3 inflammasome protects against
loss of epithelial integrity and mortality during experimental
colitis,” Immunity, vol. 32, no. 3, pp. 379–391, 2010.
[51] S. A. Hirota, J. Ng, A. Lueng et al., “NLRP3 inflammasome
plays a key role in the regulation of intestinal homeostasis,”
Inflammatory Bowel Diseases, vol. 17, no. 6, pp. 1359–1372, 2011.
[52] C. Bauer, F. Loher, M. Dauer et al., “The ICE inhibitor pral-
nacasan prevents DSS-induced colitis in C57BL/6 mice and
suppresses IP-10 mRNA but not TNF-𝛼 mRNA expression,”
Digestive Diseases and Sciences, vol. 52, no. 7, pp. 1642–1652,
2007.
[53] C. Bauer, P. Duewell, C. Mayer et al., “Colitis induced in mice
with dextran sulfate sodium (DSS) is mediated by the NLRP3
inflammasome,” Gut, vol. 59, no. 9, pp. 1192–1199, 2010.
[54] J. Henao-Mejia, E. Elinav, C. Jin et al., “Inflammasome-
mediated dysbiosis regulates progression of NAFLD and obe-
sity,” Nature, vol. 482, no. 7384, pp. 179–185, 2012.
[55] K. Matsumoto and K. Kanmatsuse, “Elevated interleukin-18
levels in the urine of nephrotic patients,” Nephron, vol. 88, no.
4, pp. 334–339, 2001.
[56] G. Lonnemann, D. Novick, M. Rubinstein, and C. A. Dinarello,
“Interleukin-18, interleukin-18 binding protein and impaired
production of interferon-𝛾 in chronic renal failure,” Clinical
Nephrology, vol. 60, no. 5, pp. 327–334, 2003.
[57] S. Gauer, O. Sichler, N. Obermu¨ller et al., “IL-18 is expressed in
the intercalated cell of human kidney,”Kidney International, vol.
72, no. 9, pp. 1081–1087, 2007.
[58] A. Vilaysane, J. Chun,M. E. Seamone et al., “TheNLRP3 inflam-
masome promotes renal inflammation and contributes to
CKD,” Journal of the American Society of Nephrology, vol. 21, no.
10, pp. 1732–1744, 2010.
[59] H.-J. Anders and D. A.Muruve, “The inflammasomes in kidney
disease,” Journal of the American Society of Nephrology, vol. 22,
no. 6, pp. 1007–1018, 2011.
[60] M. Collino, E. Benetti, M. Rogazzo et al., “Reversal of the
deleterious effects of chronic dietary HFCS-55 intake by PPAR-
delta agonism correlates with impaired NLRP3 inflammasome
activation,” Biochemical Pharmacology, vol. 85, pp. 257–264,
2013.
[61] C. Jin and R. A. Flavell, “Molecular mechanism of NLRP3
inflammasome activation,” Journal of Clinical Immunology, vol.
30, no. 5, pp. 628–631, 2010.
[62] Q.-H. Hu, X. Zhang, Y. Pan, Y.-C. Li, and L.-D. Kong, “Allop-
urinol, quercetin and rutin ameliorate renal NLRP3 inflamma-
some activation and lipid accumulation in fructose-fed rats,”
Biochemical Pharmacology, vol. 84, pp. 113–125, 2012.
[63] R. Rawat, T. V. Cohen, B. Ampong et al., “Inflammasome up-
regulation and activation in dysferlin-deficient skeletal muscle,”
American Journal of Pathology, vol. 176, no. 6, pp. 2891–2900,
2010.
[64] P. Bostro¨m, J. Wu, M. P. Jedrychowski et al., “A PGC1-𝛼-
dependent myokine that drives brown-fat-like development of
white fat and thermogenesis,” Nature, vol. 481, no. 7382, pp.
463–468, 2012.
[65] I. Lundberg, A. K. Kratz, H. Alexanderson, and M. Patar-
royo, “Decreased expression of interleukin-1alpha, interleukin-
1beta, and cell adhesion molecules in muscle tissue following
corticosteroid treatment in patients with polymyositis and
dermatomyositis,”Arthritis&Rheumatism, vol. 43, pp. 336–348,
2000.
[66] M. Tucci, C. Quatraro, F. Dammacco, and F. Silvestris, “Inter-
leukin-18 overexpression as a hallmark of the activity of autoim-
mune inflammatory myopathies,” Clinical and Experimental
Immunology, vol. 146, no. 1, pp. 21–31, 2006.
[67] J. Schmidt, K. Barthel, A. Wrede, M. Salajegheh, M. Ba¨hr, and
M.C.Dalakas, “Interrelation of inflammation andAPP in sIBM:
IL-1𝛽 induces accumulation of 𝛽-amyloid in skeletal muscle,”
Brain, vol. 131, no. 5, pp. 1228–1240, 2008.
[68] H.-M. Lakka,D. E. Laaksonen, T. A. Lakka et al., “Themetabolic
syndrome and total and cardiovascular disease mortality in
middle-aged men,” The Journal of the American Medical Asso-
ciation, vol. 288, no. 21, pp. 2709–2716, 2002.
Mediators of Inflammation 9
[69] B. Isomaa, P. Almgren, T. Tuomi et al., “Cardiovascular mor-
bidity and mortality associated with the metabolic syndrome,”
Diabetes Care, vol. 24, no. 4, pp. 683–689, 2001.
[70] A. A. W. A. van der Heijden, M. M. Ortegon, L. W. Niessen, G.
Nijpels, and J. M. Dekker, “Prediction of coronary heart disease
risk in a general, pre-diabetic, and diabetic population during 10
years of follow-up: accuracy of the Framingham, SCORE, and
UKPDS risk functions—The Hoorn Study,” Diabetes Care, vol.
32, no. 11, pp. 2094–2098, 2009.
[71] B. J. Pomerantz, L. L. Reznikov, A. H. Harken, and C. A.
Dinarello, “Inhibition of caspase 1 reduces human myocardial
ischemic dysfunction via inhibition of IL-18 and IL-1𝛽,” Pro-
ceedings of the National Academy of Sciences of the United States
of America, vol. 98, no. 5, pp. 2871–2876, 2001.
[72] S. Frantz, A. Ducharme, D. Sawyer et al., “Targeted deletion of
caspase-1 reduces early mortality and left ventricular dilatation
following myocardial infarction,” Journal of Molecular and
Cellular Cardiology, vol. 35, no. 6, pp. 685–694, 2003.
[73] F. M. Syed, H. S. Hahn, A. Odley et al., “Proapoptotic effects of
caspase-1/interleukin-converting enzyme dominate in myocar-
dial ischemia,” Circulation Research, vol. 96, no. 10, pp. 1103–
1109, 2005.
[74] S. Merkle, S. Frantz, M. P. Scho¨n et al., “A role for caspase-1 in
heart failure,” Circulation Research, vol. 100, no. 5, pp. 645–653,
2007.
[75] M. Kawaguchi, M. Takahashi, T. Hata et al., “Inflammasome
activation of cardiac fibroblasts is essential formyocardial ische-
mia/reperfusion injury,” Circulation, vol. 123, no. 6, pp. 594–
604, 2011.
[76] E. Mezzaroma, S. Toldo, D. Farkas et al., “The inflammasome
promotes adverse cardiac remodeling following acute myocar-
dial infarction in the mouse,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 108, no.
49, pp. 19725–19730, 2011.
[77] S. S. Iyer, W. P. Pulskens, J. J. Sadler et al., “Necrotic cells
trigger a sterile inflammatory response through the Nlrp3
inflammasome,”Proceedings of theNational Academy of Sciences
of theUnited States of America, vol. 106, no. 48, pp. 20388–20393,
2009.
[78] A. A. Shigeoka, J. L. Mueller, A. Kambo et al., “An inflamma-
some-independent role for epithelial-expressed Nlrp3 in renal
ischemia-reperfusion injury,” The Journal of Immunology, vol.
185, pp. 6277–6285, 2010.




Oxidative Medicine and 
Cellular Longevity











































 Computational and  
Mathematical Methods 
in Medicine
ISRN 
Allergy
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Journal of
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Biomarkers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
MEDIATORS
INFLAMMATION
of
